163 related articles for article (PubMed ID: 9636489)
21. Serum erythropoietin and parathyroid hormone concentrations in kidney transplant patients during acute graft rejection.
Kokot F; Wiecek A; Grzeszczak W; Lao M; Kuśmierski S; Cierpka L; Gradowska L; Jagiełło R
Transplant Proc; 1996 Dec; 28(6):3477-9. PubMed ID: 8962352
[No Abstract] [Full Text] [Related]
22. Renal allograft function and histology in children on triple immunosuppression based on individual pharmacokinetically determined cyclosporine administration.
Laine J; Hoppu K; Holmberg C
Transplant Proc; 1994 Oct; 26(5):2775-6. PubMed ID: 7940874
[No Abstract] [Full Text] [Related]
23. Impact of OKT3 treatment for steroid resistant rejection of renal allografts: the long-term outcome at a single center.
Inui M; Tanabe K; Ishikawa N; Tokumoto T; Harano M; Otsubo S; Suzuki K; Goya N; Yagisawa T; Nakazawa H; Fuchinoue S; Toma H
Transplant Proc; 1999 Nov; 31(7):2870-1. PubMed ID: 10578320
[No Abstract] [Full Text] [Related]
24. Conversion to tacrolimus for acute corticosteroid- and antibody-resistant rejection following kidney transplantation.
Kliem V; Radermacher J; Hiss M; Pethig M; Burg M; Brunkhorst R
Transplant Proc; 1999 Nov; 31(7A):37S-40S. PubMed ID: 10576041
[No Abstract] [Full Text] [Related]
25. Mycophenolate mofetil for the prevention of acute rejection of primary cadaveric kidney transplants: status of the MYC 1866 study at 1 year. The U.S. Mycophenolate Mofetil Study Group.
Transplant Proc; 1997; 29(1-2):348-9. PubMed ID: 9123033
[No Abstract] [Full Text] [Related]
26. Long-term outcome of tacrolimus rescue therapy in late rejection after renal transplantation.
Budde K; Smettan S; Fritsche L; Waiser J; Giessing M; Kunz R; Türk I; Bauer S; Mai I; Neumayer HH
Transplant Proc; 1998 Aug; 30(5):1780-1. PubMed ID: 9723280
[No Abstract] [Full Text] [Related]
27. Effectiveness of short-term OKT3 therapy in the treatment of steroid-resistant renal allograft rejection.
Carvalho MF; Adoni T; Saggioro FP; Soares V
Transplant Proc; 1998 Sep; 30(6):2876-7. PubMed ID: 9745607
[No Abstract] [Full Text] [Related]
28. Impact of the variability of cyclosporin A trough levels on long-term renal allograft function.
Waiser J; Slowinski T; Brinker-Paschke A; Budde K; Schreiber M; Böhler T; Hauser I; Neumayer HH
Nephrol Dial Transplant; 2002 Jul; 17(7):1310-7. PubMed ID: 12105257
[TBL] [Abstract][Full Text] [Related]
29. Predictors of improved outcome in second pediatric renal transplant recipients.
Moss A; Almond PS; Matas AJ; Gillingham K; Najarian JS
Transplant Proc; 1993 Feb; 25(1 Pt 1):597. PubMed ID: 8438429
[No Abstract] [Full Text] [Related]
30. Induction therapy with bolus ATG increases cyclosporine sensitivity in renal transplant recipients.
Varghese Z; Abudher MN; Fernando ON; Moorhead JF
Transplant Proc; 2001 May; 33(3):2251-3. PubMed ID: 11377518
[No Abstract] [Full Text] [Related]
31. Kidney transplantation in pediatric population.
Mota C; Henriques C; Sarmento M; Pereira E; Xavier E; Pereira M
Transplant Proc; 1994 Oct; 26(5):2768-70. PubMed ID: 7940872
[No Abstract] [Full Text] [Related]
32. Postmarketing evaluation of mycophenolate mofetil-based triple therapy immunosuppression compared with a conventional azathioprine-based regimen reveals enhanced efficacy and early pharmacoeconomic benefit after renal transplantation.
Wüthrich RP; Weinreich T; Schwarzkopf AK; Candinas D; Binswanger U
Transplant Proc; 1998 Dec; 30(8):4096-7. PubMed ID: 9865310
[No Abstract] [Full Text] [Related]
33. Immunosuppressive protocols at transplantation centers in Turkey.
Haberal M; Demirağ A; Bilgin N; Arslan G; Büyükpamukçu N
Transplant Proc; 1995 Oct; 27(5):2776-7. PubMed ID: 7482911
[No Abstract] [Full Text] [Related]
34. Comparison of cyclosporine monitoring with trough levels to levels obtained 6 hours after the morning dose in heart transplant patients: a prospective randomized study.
Cantarovich M; Latter D; Fitchett D
Transplant Proc; 1997; 29(1-2):602-4. PubMed ID: 9123149
[No Abstract] [Full Text] [Related]
35. Triple therapy with mycophenolate mofetil versus azathioprine.
Muñiz ML; Amenabar J; Gómez-Ullate P; Urbizu J; Lampreabe I
Transplant Proc; 1999; 31(1-2):1144-6. PubMed ID: 10083512
[No Abstract] [Full Text] [Related]
36. Case studies: conversion from Sandimmune to Neoral in stable renal allograft recipients.
Roth D; Miller J
Transplant Proc; 1996 Aug; 28(4):2219-20; discussion 2218. PubMed ID: 8769204
[No Abstract] [Full Text] [Related]
37. Association between anti-thymocyte globulin administration and cytomegalic virus infection and/or CMV disease in cadaveric renal allograft recipients.
Siu CW; Chan TM; Li FK; Choy BY; Lui SL; Lo CY; Tang S; Lo WK; Lai KN
Transplant Proc; 2000 Nov; 32(7):1932-4. PubMed ID: 11120007
[No Abstract] [Full Text] [Related]
38. A randomized study comparing three cyclosporine-based regimens in cadaveric renal transplantation: results at 7 years.
Tarantino A; Segoloni GP; Cambi V; Rizzo G; Altieri P; Mastrangelo F; Castagneto M; Salvadori M; Valente U; Cossu M; Federico S; Pisani F; Montagnino G; Messina M; Arisi L; Carmellini M; Piredda GB; Ponticelli C
Transplant Proc; 1998 Aug; 30(5):1729-31. PubMed ID: 9723258
[No Abstract] [Full Text] [Related]
39. The impact of induction therapy HLA matching and T- and B-cell crossmatch on the long-term outcome of living donated renal transplantation.
Lumlertgul D; Manoyos A; Saikum U; Chaovisitsaree A; Boonkaew S; Wongsawad P; Bunnachak D; Roachanapiwat B; Wutikarn S
Transplant Proc; 1998 Aug; 30(5):1801-4. PubMed ID: 9723290
[No Abstract] [Full Text] [Related]
40. Long-term follow-up (5 and 10 years) in recipients of HLA identical living related donor kidney grafts receiving continuous cyclosporine compared with azathioprine.
MacDonald AS; Belitsky P; Bitter-Suermann H; Lawen J; MacSween M; Kiberd B; West K; McAlister VC
Transplant Proc; 1997; 29(1-2):190. PubMed ID: 9122958
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
